Clinical Trials Browser

Approved for marketing × Multiple Myeloma × talquetamab × Clear all

NCT05757973 2025-12-09

Pre-Approval Access Program for Talquetamab in Relapsed or Refractory Multiple Myeloma

Approved for marketing

Multiple Myeloma, Recurrence